Jessica R Salas1,2, Bao Ying Chen1,2, Alicia Wong1,2, Donghui Cheng3, John S Van Arnam4, Owen N Witte1,3,5, Peter M Clark6,2,3. 1. Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California. 2. Crump Institute for Molecular Imaging, UCLA, Los Angeles, California. 3. Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, UCLA, Los Angeles, California. 4. Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; and. 5. Department of Microbiology, Immunology, and Molecular Genetics, UCLA, Los Angeles, California. 6. Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California pclark@mednet.ucla.edu.
Abstract
Immune cell-mediated attack on the liver is a defining feature of autoimmune hepatitis and hepatic allograft rejection. Despite an assortment of diagnostic tools, invasive biopsies remain the only method for identifying immune cells in the liver. We evaluated whether PET imaging with radiotracers that quantify immune activation (18F-FDG and 18F-1-(2'-deoxy-2'-fluoro-arabinofuranosyl)cytosine [18F-FAC]) and hepatocyte biology (18F-2-deoxy-2-fluoroarabinose [18F-DFA]) can visualize and quantify liver-infiltrating immune cells and hepatocyte inflammation, respectively, in a preclinical model of autoimmune hepatitis. Methods: Mice treated with concanavalin A (ConA) to induce a model of autoimmune hepatitis or vehicle were imaged with 18F-FDG, 18F-FAC, and 18F-DFA PET. Immunohistochemistry, digital autoradiography, and ex vivo accumulation assays were used to localize areas of altered radiotracer accumulation in the liver. For comparison, mice treated with an adenovirus to induce a viral hepatitis were imaged with 18F-FDG, 18F-FAC, and 18F-DFA PET. 18F-FAC PET was performed on mice treated with ConA and vehicle or with ConA and dexamethasone. Biopsy samples of patients with autoimmune hepatitis were immunostained for deoxycytidine kinase. Results: Hepatic accumulation of 18F-FDG and 18F-FAC was 173% and 61% higher, respectively, and hepatic accumulation of 18F-DFA was 41% lower, in a mouse model of autoimmune hepatitis than in control mice. Increased hepatic 18F-FDG accumulation was localized to infiltrating leukocytes and inflamed sinusoidal endothelial cells, increased hepatic 18F-FAC accumulation was concentrated in infiltrating CD4 and CD8 cells, and decreased hepatic 18F-DFA accumulation was apparent in hepatocytes throughout the liver. In contrast, viral hepatitis increased hepatic 18F-FDG accumulation by 109% and decreased hepatic 18F-DFA accumulation by 20% but had no effect on hepatic 18F-FAC accumulation (nonsignificant 2% decrease). 18F-FAC PET provided a noninvasive biomarker of the efficacy of dexamethasone for treating the autoimmune hepatitis model. Infiltrating leukocytes in liver biopsy samples from patients with autoimmune hepatitis express high levels of deoxycytidine kinase, a rate-limiting enzyme in the accumulation of 18F-FAC. Conclusion: Our data suggest that PET can be used to noninvasively visualize activated leukocytes and inflamed hepatocytes in a mouse model of autoimmune hepatitis.
Immune cell-mediated attack on the liver is a defining feature of autoimmune hepatitis and hepatic allograft rejection. Despite an assortment of diagnostic tools, invasive biopsies remain the only method for identifying immune cells in the liver. We evaluated whether PET imaging with radiotracers that quantify immune activation (18F-FDG and 18F-1-(2'-deoxy-2'-fluoro-arabinofuranosyl)cytosine [18F-FAC]) and hepatocyte biology (18F-2-deoxy-2-fluoroarabinose [18F-DFA]) can visualize and quantify liver-infiltrating immune cells and hepatocyte inflammation, respectively, in a preclinical model of autoimmune hepatitis. Methods:Mice treated with concanavalin A (ConA) to induce a model of autoimmune hepatitis or vehicle were imaged with 18F-FDG, 18F-FAC, and 18F-DFA PET. Immunohistochemistry, digital autoradiography, and ex vivo accumulation assays were used to localize areas of altered radiotracer accumulation in the liver. For comparison, mice treated with an adenovirus to induce a viral hepatitis were imaged with 18F-FDG, 18F-FAC, and 18F-DFA PET. 18F-FAC PET was performed on mice treated with ConA and vehicle or with ConA and dexamethasone. Biopsy samples of patients with autoimmune hepatitis were immunostained for deoxycytidine kinase. Results: Hepatic accumulation of 18F-FDG and 18F-FAC was 173% and 61% higher, respectively, and hepatic accumulation of 18F-DFA was 41% lower, in a mouse model of autoimmune hepatitis than in control mice. Increased hepatic 18F-FDG accumulation was localized to infiltrating leukocytes and inflamed sinusoidal endothelial cells, increased hepatic 18F-FAC accumulation was concentrated in infiltrating CD4 and CD8 cells, and decreased hepatic 18F-DFA accumulation was apparent in hepatocytes throughout the liver. In contrast, viral hepatitis increased hepatic 18F-FDG accumulation by 109% and decreased hepatic 18F-DFA accumulation by 20% but had no effect on hepatic 18F-FAC accumulation (nonsignificant 2% decrease). 18F-FAC PET provided a noninvasive biomarker of the efficacy of dexamethasone for treating the autoimmune hepatitis model. Infiltrating leukocytes in liver biopsy samples from patients with autoimmune hepatitis express high levels of deoxycytidine kinase, a rate-limiting enzyme in the accumulation of 18F-FAC. Conclusion: Our data suggest that PET can be used to noninvasively visualize activated leukocytes and inflamed hepatocytes in a mouse model of autoimmune hepatitis.
Authors: Yoshifumi Maya; Rudolf A Werner; Claudia Schütz; Hiroshi Wakabayashi; Samuel Samnick; Constantin Lapa; Christina Zechmeister; Roland Jahns; Valérie Jahns; Takahiro Higuchi Journal: J Nucl Med Date: 2016-07-07 Impact factor: 10.057
Authors: Peter M Clark; Victoria A Ebiana; Laura Gosa; Timothy F Cloughesy; David A Nathanson Journal: J Nucl Med Date: 2017-04-06 Impact factor: 10.057
Authors: Sarah Brewer; Michael McPherson; Daisuke Fujiwara; Olga Turovskaya; David Ziring; Ling Chen; Hidetoshi Takedatsu; Stephan R Targan; Bo Wei; Jonathan Braun Journal: Gastroenterology Date: 2008-07-17 Impact factor: 22.682
Authors: Bao Ying Chen; Chiara Ghezzi; Brendon Villegas; Andrew Quon; Caius G Radu; Owen N Witte; Peter M Clark Journal: J Nucl Med Date: 2019-10-25 Impact factor: 10.057
Authors: Liang Wang; Bryan A Smith; Nikolas G Balanis; Brandon L Tsai; Kim Nguyen; Michael W Cheng; Matthew B Obusan; Favour N Esedebe; Saahil J Patel; Hanwei Zhang; Peter M Clark; Anthony E Sisk; Jonathan W Said; Jiaoti Huang; Thomas G Graeber; Owen N Witte; Arnold I Chin; Jung Wook Park Journal: Proc Natl Acad Sci U S A Date: 2019-12-23 Impact factor: 11.205
Authors: Caroline Guglielmetti; Jelena Levi; Tony L Huynh; Brice Tiret; Joseph Blecha; Ryan Tang; Henry VanBrocklin; Myriam M Chaumeil Journal: J Nucl Med Date: 2021-04-09 Impact factor: 11.082